Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

A six-mer synthetic peptide (AT1002) showed enhanced nasal drug delivery | LifeTein Peptide Blog

Zonula occludens toxin (Zot) and its biologically active fragment, delta G, have been shown to reversibly open tight junctions (TJ) in endothelial and epithelial cells. AT1002, a six-mer synthetic peptide H-FCIGRL-OH of ZO toxin, was identified and synthesized

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Zonula occludens toxin (Zot) and its biologically active fragment, delta G, have been shown to reversibly open tight junctions (TJ) in endothelial and epithelial cells. AT1002, a six-mer synthetic peptide H-FCIGRL-OH of ZO toxin, was identified and synthesized to retain the Zot permeating effect on intercellular TJ. It was found that AT1002 disrupts the epithelial barrier while larazotide acetate restores barrier function by rearrangement of actin. In addition, AT1002 enhances the transport of molecular weight markers or agents with low bioavailability with no cytotoxicity. So, this synthetic peptide AT1002 is a tight junction modulator with promising permeation-enhancing activity.

A Synthetic Peptide Showed Enhanced Nasal Drug Delivery

The C-terminal amidated AT1002 FCIGRL-NH2 showed enhanced nasal drug delivery and may lead to the development of a practical drug delivery technology for drugs with low bioavailability.

LifeTein synthesized the synthetic peptide AT1002.

Peptide amidation

https://bmcbiol.biomedcentral.com/articles/10.1186/s12915-018-0481-z

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383222/

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →